Literature DB >> 14726144

Alternative sugars as potential carriers for dry powder inhalations.

Hartwig Steckel1, Nina Bolzen.   

Abstract

Most dry powder inhaler (DPI) formulations rely on lactose monohydrate as a carrier in the drug powder blends. However, lactose cannot be used for compounds that interact with the reducing sugar function of the lactose, such as formoterol, budesonide or peptides and proteins. In this study, alternative carriers like mannitol, glucose, sorbitol, maltitol and xylitol have therefore been evaluated for their potential use in DPI formulations. Raw materials were characterised physico-chemically and blends with the model drug substance budesonide were tested with respect to the aerosolization behaviour of the powders. It was found out that similarly to the problems known for lactose monohydrate, such as supplier variability, variability between different qualities of one supplier, the same difficulties apply to the alternative carriers investigated. Different sources and qualities of mannitol led to significant differences in the fine particle fraction (FPF), varying from 15 to 50% for two different qualities of mannitol. Similar observations were made for the other carrier materials studied. Also, the influence of conditioning the raw material at different relative humidity was found to have substantial influence on the performance of drug/carrier blends which is characterised by a strong decrease in the FPF. In summary, mannitol showed potential as a drug carrier to be used in DPIs whereas the more hygroscopic sugars only showed poor dispersibility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726144     DOI: 10.1016/j.ijpharm.2003.10.039

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

1.  Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.

Authors:  V N P Le; T H Hoang Thi; E Robins; M P Flament
Journal:  AAPS PharmSciTech       Date:  2012-03-08       Impact factor: 3.246

Review 2.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides.

Authors:  Alamdar Hussain; Quamrul H Majumder; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2006-12-07       Impact factor: 4.200

4.  An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.

Authors:  Matthew D Jones; Jennifer C Hooton; Michelle L Dawson; Alan R Ferrie; Robert Price
Journal:  Pharm Res       Date:  2007-10-19       Impact factor: 4.200

5.  Inhalable lactose-based dry powder formulations of low molecular weight heparin.

Authors:  Shuhua Bai; Vivek Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

6.  Aerodynamic and electrostatic properties of model dry powder aerosols: a comprehensive study of formulation factors.

Authors:  M J Telko; A J Hickey
Journal:  AAPS PharmSciTech       Date:  2014-06-18       Impact factor: 3.246

7.  Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.

Authors:  Xiaojian Li; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2011-10-25       Impact factor: 3.246

Review 8.  Lactose engineering for better performance in dry powder inhalers.

Authors:  Yahya Rahimpour; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2012-08-15

9.  Effect of cholesterol on the properties of spray-dried lysozyme-loaded liposomal powders.

Authors:  Dusadee Charnvanich; Nontima Vardhanabhuti; Poj Kulvanich
Journal:  AAPS PharmSciTech       Date:  2010-05-13       Impact factor: 3.246

Review 10.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.